Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zoey Glick

Dermatology Williamsville, NY Medical Doctor

NPI 1770726606 CMS profile 1154333

425 Essjay Rd Ste 130, Williamsville, NY 14221

Open in the dashboard

General payments

$6,013

286 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zoey Glick of Williamsville, NY is reported in the CMS Open Payments database as having received $6,013 across 286 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $524 26
2024 General $976 46
2023 General $538 24
2022 General $902 44
2021 General $793 41
2020 General $711 35
2019 General $1,571 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zoey Glick
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Zoey Glick were reported at $524. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Zoey Glick Dermatology median Middle half National median
2019 $1,571 $454 $129–$1,240 $163
2020 $711 $235 $81–$756 $114
2021 $793 $377 $108–$1,108 $132
2022 $902 $514 $143–$1,391 $149
2023 $538 $607 $159–$1,674 $160
2024 $976 $751 $204–$1,903 $164
2025 $524 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $1,173 64 payments
  2. Regeneron Healthcare Solutions, Inc. $727 24 payments
  3. AbbVie, Inc. $430 20 payments
  4. Allergan Inc. $395 14 payments
  5. Amgen Inc. $354 18 payments
  6. Genzyme Corporation $334 16 payments
  7. Pfizer Inc. $329 17 payments
  8. Galderma Laboratories, L.P. $318 22 payments
  9. Novartis Pharmaceuticals Corporation $283 14 payments
  10. Merz North America, Inc. $259 5 payments
  11. Other $1,411 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,134 277 payments
  2. Education $596 8 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $283 1 payment
Products named General payments · program years 2019–2025
  1. TREMFYA $1,133 61 payments
  2. DUPIXENT Inflammation And Immunology $656 22 payments
  3. DUPIXENT Immunology $391 16 payments
  4. Otezla $354 18 payments
  5. EUCRISA $256 15 payments
  6. Xeomin $231 3 payments
  7. ASCLERA $208 2 payments
  8. SKYRIZI $200 9 payments
  9. COSENTYX $180 10 payments
  10. CIBINQO $163 6 payments
  11. Other $2,440 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,369

Median for Dermatology: 534

Drug cost

$172,212

Median for Dermatology: $67,151

Branded share of claims

7.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 21 $138,110
Fluorouracil Generic 101 $8,045
Gentamicin Sulfate Generic 74 $4,553
Clobetasol Propionate Generic 110 $2,837
Ketoconazole Generic 103 $2,757
Betamethasone Dipropionate Generic 39 $2,555
Clindamycin Phosphate Generic 64 $2,355
Tacrolimus Generic 12 $1,288
Triamcinolone Acetonide Generic 128 $1,137
Metronidazole Generic 22 $1,117

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$66,790

Medicare's payments for the services billed

Medicare patients

279

Average age 72

Services billed

1,323

175 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 42%
Depression 25%
Chronic kidney disease 24%
Diabetes 20%
Ischemic heart disease 16%
Cancer 15%
COPD 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $236
$236 — —
TREMFYA
  • Janssen Biotech, Inc. $235
$235 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $145
$145 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $99
$99 — —
Bimzelx
  • UCB, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

286 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record